1160247-03-9

Basic information

• Product Name: 2-oxo-4-oxa-1,9-diaza-spiro[5.5]undecane-9-carboxylic acid tert-butyl ester
• Synonyms: 2-oxo-4-oxa-1,9-diaza-spiro[5.5]undecane-9-carboxylic acid tert-butyl ester
• CAS NO: 1160247-03-9
• Molecular Weight: 270.329
• Mol File: 1160247-03-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-oxo-4-oxa-1,9-diaza-spiro[5.5]undecane-9-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-oxo-4-oxa-1,9-diaza-spiro[5.5]undecane-9-carboxylic acid tert-butyl ester(1160247-03-9)
• EPA Substance Registry System: 2-oxo-4-oxa-1,9-diaza-spiro[5.5]undecane-9-carboxylic acid tert-butyl ester(1160247-03-9)

Safety Data

• Hazardous Substances Data: 1160247-03-9(Hazardous Substances Data)

Usage

General Description

2-oxo-4-oxa-1,9-diaza-spiro[5.5]undecane-9-carboxylic acid tert-butyl ester is a chemical compound with a complex molecular structure. It contains a spirocyclic ring system with a diaza and oxa moiety, as well as a carboxylic acid functional group and a tert-butyl ester. 2-oxo-4-oxa-1,9-diaza-spiro[5.5]undecane-9-carboxylic acid tert-butyl ester may have potential applications in medicinal chemistry, as spirocyclic compounds are known for their diverse biological activities. Additionally, the presence of a carboxylic acid group makes it a potentially useful building block for the synthesis of other organic molecules. However, due to its complex structure, this compound may pose challenges in its synthesis and handling in the laboratory.

Upstream product

• 203186-96-3 tert-butyl 4-amino-4-(hydroxymethyl)piperidine-1-carboxylate 
• 183673-71-4 4-amino-1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1169699-61-9 9-benzyl-4-oxa-1,9-diaza-spiro[5.5]undecan-2-one 
• 1391602-69-9 N-(1-benzyl-4-hydroxymethyl-piperidin-4-yl)-2-chloro-acetamide 
• 312928-52-2 (4-amino-1-benzyl-piperidin-4-yl)-methanol 
• 28936-94-9 8-benzyl-1,3,8-triaza-spiro[4.5]decane-2,4-dione 
• 39143-25-4 1-benzyl-4-amino-4-piperidinecarboxylic acid 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 1391602-71-3 1-methyl-4-oxa-1,9-diaza-spiro[5,5]undecan-2-one hydrochloride 

Relevant articles and documents

Discovery of 3-chlorobenzyl-linked 1,9-diazaspiro[5.5]undecane derivatives, a lead for dengue virus type 2 infection

Dengue virus poses a serious worldwide health threat with up to 400 million infections occurring annually in over 100 countries. Currently, there are no specific therapeutics available, and the only licensed vaccine is used to mitigate the risk of hospitalization in immunologically naive individuals. In the current work, for the first time we are reporting dengue virus type 2 (DENV2) inhibitory activity in newly designed 3-chlorobenzyl-linked 1,9-diazaspiro[5.5]undecane derivatives. Compounds with substitutions featuring 2-methylbenzyl (SPO-6, EC50 = 11.43 ± 0.87 μM), 4-bromobenzyl (SPO-7, EC50 = 14.15 ± 0.50 μM), and 4-cyanobenzyl (SPO-13, EC50 = 20.77 ± 1.92 μM) groups and the antiviral drug ribavirin (IC50 = 50.9 ± 18 μM, J. Gen. Virol., 2006, 87, 1947–1952) were found to be potent against DENV2 in a cell-based assay. Docking calculations identified NS5-methyltransferase as the most probable target for this series of compounds. Molecular dynamics simulations of NS5-methyltransferase reproduced the experimental binding affinity findings by yielding ΔGbind values that predicted SPO-6 to possess the most favorable binding energy of ?27.2 ± 3.9 kcal mol?1 compared with SPO-7, SPO-13 and ribavirin with ?22.5 ± 4.7, ?22.5 ± 4.6 and ?20.0 ± 4.6 kcal mol?1, respectively. In addition, based on Lipinski's rule of five, SPO-6 was found to be non-toxic and possessed a better drug-likeness score (5.87) in comparison with the standard drug ribavirin (1.72).

SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R1, R2, R4, R3, R5 and R6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.